52 results about "Lurasidone Hydrochloride" patented technology

The invention belongs to the technical field of medicine, and relates to a lurasidone hydrochloride orally-disintegrating tablet preparation and a preparation method thereof. The orally-disintegrating tablet comprises the following components in mass percent: 5-60 percent of lurasidone hydrochloride, 25-80 percent of filling material, 5-20 percent of disintegrating agent, 0.02-0.15 percent of wetting agent, 0.2-5 percent of flavoring agent and 0.5-2 percent of lubricating agent. The invention aims to provide a lurasidone hydrochloride orally-disintegrating tablet with simple preparation process, low cost, convenience in use and quick action to the indications; and compared with the conventional preparation for oral use, the lurasidone hydrochloride orally-disintegrating tablet preparation can reduce the difficulty in swallowing, improve the compliance, is suitable for special populations such as the elderly, children, patients with difficulty in swallowing and mental patients, can be fully disintegrated within 60 s, can be disintegrated into extremely fine powder, is higher in drug dissolution rate and quick in absorption, and can improve the bioavailability of insoluble drugs, for example, lurasidone hydrochloride.

The invention relates to orally disintegrating tablets containing lurasidone and a preparation method thereof. The orally disintegrating tablets comprise lurasidone hydrochloride, filler, disintegrant, flavoring agent and lubricant, wherein the grain diameter D90 of the lurasidone hydrochloride is less than or equal to 75 mu m. The lurasidone orally disintegrating tablets have good dissolution in vitro and excellent taste; the orally disintegrating tables are simple in preparation process, and industrial production can be realized by adopting conventional granulation and tabletting equipment.

The invention relates to an oral preparation and a preparation method thereof. The preparation contains lurasidone hydrochloride, a micronized particle of a dispersion supporter, microcrystalline cellulose and a water-soluble polymer adhesive. More specifically, the invention relates to the oral preparation and especially to a tablet. The preparation has a fast dissolution characteristic, and dissolution characteristics of an active component are identical; even though the content of the active component in the preparation changes in a certain range, the dissolution characteristics of the active component are still identical.

The present invention discloses a preparation method for lurasidone hydrochloride represented by a formula (I). The method comprises the following steps: adopting a mixture to treat a solution formed by dissolving a compound (II) in a dialkyl ketone solvent having carbon number not more than 6, and carrying out crystallization to obtain the product of the present invention, wherein the mixture comprise an organic solvent capable of mixing and dissolving with water and hydrochloric acid, a mass ratio of the organic solvent to the hydrochloric acid is 0.5:1-100:1, a molar ratio of hydrogen chloride in the hydrochloric acid to the compound II is 10:1-0.9:1. The preparation method of the present invention has the following advantages that: durability is significantly improved, the prepared lurasidone hydrochloride (the compound I) has characteristics of high purity, low residual acetone, and high yield, and the method is economical and is suitable for industrial production.

The invention belongs to the field of pharmaceutic preparations, and particularly relates to a sustained-release suspension composition with lurasidone or salt of the lurasidone and a preparation method of the sustained-release suspension composition. A sustained-release suspension comprises the lurasidone or the salt, capable of being medically accepted, of the lurasidone and a sustained-release micro-capsule coating material medicine composition. According to the preparation, the release time of lurasidone hydrochloride is effectively prolonged, and the blood concentration peak valley phenomenon caused by quick release preparations is avoided. The sustained-release suspension with the lurasidone is low in production cost and has the good taste and medicine release character, the preparation process of the sustained-release suspension with the lurasidone is convenient, and the aim of providing the preparation with the lurasidone or the salt, capable of being medically accepted, of the lurasidone for a patient is achieved, wherein the preparation is convenient to take, high in bioavailability and mild in medicine release.

The invention provides a lurasidone hydrochloride orally disintegrating tablet containing indissolvable drugs. The lurasidone hydrochloride orally disintegrating tablet comprises 8%-24% of lurasidone hydrochloride, 8%-48% of a carrier, 0.8%-4% of adhesive, 24%-76.2% of filler, 4%-10% of a disintegrating agent, 2%-6% of flavoring agent and 1%-4% of a lubricating agent. The lurasidone hydrochloride orally disintegrating tablet can be disintegrated quickly, and convenience is provided for medicine taking of patients particularly like the aged, children, coma patients and the patients who cannot take water conveniently. Moreover, the dissolving-out rate can reach 85% or above within 5 minutes. In addition, the lurasidone hydrochloride orally disintegrating tablet can be disintegrated and absorbed quickly in the oral cavity, so that the bioavailability is greatly improved. Operation is easy in production technology, the production cost is low, and the lurasidone hydrochloride orally disintegrating tablet is suitable for industrial mass production.

The invention relates to a lurasidone hydrochloride crystal form as well as a preparation method and application thereof. Specifically, the invention discloses a lurasidone hydrochloride crystal form, and a preparation method, a pharmaceutical composition and a pharmaceutical purpose thereof. An XRD characteristic peak of the lurasidone hydrochloride crystal form is as shown in figure I. The lurasidone hydrochloride crystal form provided by the invention is stable in character, good in repeatability and suitable for drug development.

Disclosed is a new and efficient process for the synthesis with high yields and purity of lurasidone hydrochloride, a medicament which is useful as a psychotropic substance. The process involves the preparation of lurasidone base in a reaction system not containing inorganic salts, followed by conversion of the latter to an addition salt with an organic carboxylic acid, which is finally converted to lurasidone hydrochloride.

The invention relates to a method for preparing lurasidone and a salt thereof. The method comprises the following steps: reacting (R,R)-1,2-bis(methanesulfonyloxymethyl)cyclohexane and 3-(1-piperazinyl)-1,2-benzoisothiazole hydrochloride in acetonitrile in the presence of potassium carbonate to obtain an intermediate I; reacting the intermediate I with (3aR,4S,7R,7aS)-4,7-methylene-1H-isoindole-1,3(2H)-dione in DMF in the presence of potassium carbonate to prepare lurasidone free alkali; and reacting the lurasidone free alkali with hydrochloric acid in isopropanol to obtain lurasidone hydrochloride. The invention also relates to lurasidone and the salt thereof prepared by using the method, and application of lurasidone and the salt thereof in medicines for resisting psychosis, especially schizophrenia. The method disclosed by the invention has one or more advantages in a group consisting of simple process, high product yield, few impurities and the like.

The invention discloses a lurasidone hydrochloride nano mixed suspension solution for durable intramuscular injection and a preparation method of the nano mixed suspension solution. The raw materialsof the nano mixed suspension solution comprise 0.1-0.5 wt.% of lurasidone hydrochloride and 0.1-0.3 wt.% of a stabilizer, and a solvent is water for injection. Through high-speed dispersion, in combination with a wet-method medium grinding method, the lurasidone hydrochloride is prepared into the nano mixed suspension solution for intramuscular injection, the first-pass effect is avoided, and thesolubility and dissolution rate of the medicine after muscle injection are improved. After muscle injection, the effect can be achieved continuously for 3-7 days, the drug administration frequency isreduced, fluctuation of the plasma drug concentration is reduced, and the compliance and safety of a patient during medicine taking are improved.

The invention discloses a method for preparing a lurasidone hydrochloride intermediate (formula I). (S,R)-p-toluene sulfonic acid cyclohexane dimethyl ester (formula II) and benzisothiazole piperazine (formula III) are dissolved in an aprotic polar solvent, a basic catalyst is used to serve as an acid binding agent, and heating reaction is performed for 10-24 h. The proper aprotic polar solvent is adopted to serve as a reaction medium for substitution reaction, a mixed feeding method is adopted, so that the reaction is performed quickly, the content of chiral impurities is low, and a postprocessing process is simple and convenient.

The invention discloses a sublingual tablet containing lurasidone hydrochloride or salt thereof and a preparation method of the sublingual tablet. The sublingual tablet is prepared from the following raw materials in parts by mass: 4 to 8 parts of lurasidone or a salt thereof, 2 to 6 parts of sorbitol, 4 to 8 parts of mannitol, 0.5 to 1.5 parts of polyvinylpolypyrrolidone, 0.1 to 0.5 part of hydroxy propyl cellulose, 0.1 to 0.2 part of aspartame and 0.1 to 0.2 part of magnesium stearate, wherein the particle size range of the lurasidone or the salt thereof is 0.1 to 10 microns. The sublingual tablet disclosed by the invention is convenient in preparation process, high in drug content, high in disintegration speed, good in permeable membrane absorption and good in in-vitro dissolution and taste, and a preparation containing lurasidone or salt thereof, which is convenient to take, quick to absorb and high in bioavailability, can be provided for patients.

The invention provides a preparation method of lurasidone hydrochloride. The method comprises the step of reacting lurasidone free alkali with hydrochloric acid in a mixed solvent of an alcohol solvent and a haloalkane solvent to obtain the lurasidone hydrochloride. The method provided by the invention has the advantages of high yield, low cost, high safety and low residual solvent content, and is very suitable for industrial production.

The invention belongs to the technical field of pharmaceutical preparations and particularly relates to lurasidone hydrochloride tablets and a preparation method thereof. The tablets take lurasidone hydrochloride as an active component and consist of the lurasidone hydrochloride, a filling agent, copovidone, cross-linked povidone and a lubricant. According to the lurasidone hydrochloride tablets and the preparation method thereof, based on physicochemical property characteristics of the lurasidone hydrochloride, the hydrogen bond association effect between the copovidone and the cross-linked povidone and the lurasidone hydrochloride is utilized, the recrystallization rate of the medicine is inhibited, the dissolution rate of the medicine is improved, and the bioavailability of the medicine is guaranteed. Simultaneously, the invention further discloses a preparation process of the lurasidone hydrochloride tablets. The preparation process is simple, has good reproducibility and is suitable for industrial production.

The present invention provides an improved process for preparation of the substantially pure (3aR,7aR)-4′-(benzo[d]isothiazol-3-yl)octahydrospiro[isoindole-2,1′-piperazin]-1′-ium methanesulfonate (referred to as compound-II), which is useful as a key intermediate for the synthesis of lurasidone ((3aR,4S,7R,7aS)-2-{(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)piperazin-1ylmethyl]cyclohexylmethyl}hexahydro-4,7-methano-2H-isoindole-1,3-dione). The process comprises reaction of the compound-III (as described herein) with the compound-IV (as described herein) in the presence of a solvent mixture selected from an alcohol and water; and a base The improved process for the preparation of compound II provides the product with total amount of unreacted compound-IV as impurity in less than 0.06% and the product with HPLC purity as ≧99.8%. The process further refers purification of Lurasidone hydrochloride, wherein the product contains the residual acetone <5000 ppm.